Helping our patient communities and advancing knowledge in our therapy areas is part of our corporate responsibility.
It is our mission to discover, develop, and deliver innovative therapies that improve patients' quality of life.
Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise.
See the research that is done to find out if medical treatments can improve people's health.
Every day at CSL Behring, we work as if someone's life depends on it, because it does.
CSL Behring biotherapies are manufactured in state-of-the-art facilities under stringent, controlled conditions
Help us deliver on our promise to save lives and protect the health of people.
Make you well-being a priority. It's important and so are you.
Vita means life. In this section, we share stories aimed at providing insight about, and awareness of, the ever-evolving promise of biotechnology.
Visit CSL Behring's newsroom to find recent news releases, archived releases, and media contacts.
News from CSL Behring
CSL continues to provide medicines to patients around the world.
CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in support of Indonesian earthquake and tsunam…
Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global Diversity and Inclusion Index
HIZENTRA, the First Subcutaneous Immunoglobulin (SCIg) Approved for CIDP
CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to the World Federation of Haemophilia
The AEGIS-II trial will enrol more than 17,000 patients from approximately 1,000 medical centers around the world.
Global biotech leader rated at no. 42 for patient focus, innovation and sustainable growth
CSL Behring today announced that it has signed an agreement with the National Blood Authority, representing all Australian go…
CSL today officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows wit…
Popular search terms:
Americas
Asia Pacific
Europe
